BioSante Pharmaceuticals Announces Issuance of New Patent Covering Elestrin(TM) and LibiGel(R) (RedNova)
BioSante Pharmaceuticals, Inc. (Amex:BPA) annou

Pfizer and Mylan Fight to Defend Norvasc Against Generics (SeekingAlpha via Yahoo! Finance)
Aaron F. Barkoff submits: A dozen companies have submitted letters in response to FDA's March 29 request for "comments from interested parties" on Norvasc exclusivity issues. Last week, as we reported here, FDA promised the U.S.

BioSante Pharmaceuticals Announces Issuance of New Patent Covering Elestrin(TM) and LibiGel(R) (Business Wire via Yahoo! Finance)
LINCOLNSHIRE, Ill.----BioSante Pharmaceuticals, Inc. announced that a new patent has issued covering the formulations used in Elestrin , BioSante's newly approved treatment for moderate to severe vasomotor symptoms associated with menopause and LibiGel , which recently moved into Phase III clinical development for the treatment of female sexual dysfunction.